Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Hinova Pharmaceuticals divulges new BRD4 and AR dual inhibitors

Oct. 20, 2020

Midatech presents phase I data for MTX-110 in diffuse intrinsic pontine glioma

Oct. 20, 2020

SWI/SNF mutations can lead to gain of function

Oct. 20, 2020

Aptose begins phase Ia/b study of CG-806 in AML

Oct. 19, 2020

Agios withdraws MAA for Tibsovo for relapsed or refractory AML with IDH1 mutation

Oct. 19, 2020

Epizyme presents CREBBP and KAT3B inhibitors

Oct. 19, 2020

Insilico Medicine discloses JAK inhibitors

Oct. 19, 2020

Medshine Discovery patents Ret inhibitors

Oct. 19, 2020

Bromodomain 2-selective BET inhibitors show antitumor effect in pediatric cancer models

Oct. 19, 2020

FDA accepts IND for phase I/II study of Nuvation's NUV-422 in high-grade gliomas

Oct. 16, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...